European expansion Pepaxti is being commercialized in Europe with active partnerships for South Korea, the Middle East and Africa and elsewhere, signaling ongoing international commercialization and potential distribution channel opportunities.

Strategic partnerships Recent collaboration with Salus Group for distribution in Central and Eastern Europe indicates a proven model for regional sales acceleration that can be leveraged with additional distributors in other regions.

Clinical pipeline Strong emphasis on two proprietary platforms PDC and SPiKE with multiple new candidates in development, offering opportunities to upsell collaborations, co-development, or milestone-driven partnerships around novel therapies.

Financial readiness Revenue growth in Q2 2026 and a healthy funding runway position (funding of 240M) suggest capacity for scaled market entry activities, partnerships, and joint ventures to expand Pepaxti adoption.

Key events Active conference presence at EHA 2026 and disclosed clinical and translational data plans create avenues for sponsorable studies, sponsored presentations, and targeted outreach to hematology/oncology buyers.